e-learning
resources
Vienna 2009
Sunday, 13.09.2009
COPD: basic science and clinical studies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
SELDI-TOF MS for proteomic analysis of exhaled breath condensate from patients with pulmonary emphysema
M. Fumagalli, F. Ferrari, E. Ansaldo, L. Fregonese, S. Viglio, I. Cerveri, M. Luisetti, J. Stolk, P. Iadarola (Pavia, Italy; Leiden, Netherlands)
Source:
Annual Congress 2009 - COPD: basic science and clinical studies
Session:
COPD: basic science and clinical studies
Session type:
Thematic Poster Session
Number:
905
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Fumagalli, F. Ferrari, E. Ansaldo, L. Fregonese, S. Viglio, I. Cerveri, M. Luisetti, J. Stolk, P. Iadarola (Pavia, Italy; Leiden, Netherlands). SELDI-TOF MS for proteomic analysis of exhaled breath condensate from patients with pulmonary emphysema. Eur Respir J 2009; 34: Suppl. 53, 905
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Diagnosis of lung diseases based on proteomic analysis of exhaled breath condensate
Source: International Congress 2017 – Clinical problems in lung diseases
Year: 2017
Discrimination of protein and peptide composition of exhaled breath condensate in patients with pulmonary disease by mass spectrometry
Source: Annual Congress 2011 - Role of the biomarkers in airway diseases
Year: 2011
Lung disease diagnostic method based on proteomic analysis of exhaled breath condensate
Source: International Congress 2019 – Basic research of airway diseases
Year: 2019
Metabolomic analysis of exhaled breath condensate in diagnostics of obstructive airway diseases
Source: Annual Congress 2011 - Role of the biomarkers in airway diseases
Year: 2011
Processing optimization of exhaled breath condensate previous to the analysis by mass spectrometry
Source: Annual Congress 2012 - Mechanics, muscles and movement: aspects of airway mechanics, repiratory muscle assessment and field exercise tests
Year: 2012
Human skin keratins are the major proteins in exhaled breath condensate
Source: Eur Respir J 2008; 31: 380-384
Year: 2008
Changes in exhaled breath condensate in asthma and COPD: A full analysis of mass-spectra
Source: Annual Congress 2010 - Exhaled biomarkers: smells like disease
Year: 2010
Analysis of exhaled breath condensate proteom and BAL Proteom by matrix assisted laser desorption/ioniosation – time of flight (MALDI-TOF) from patients with acute lung injury
Source: Annual Congress 2003 - Mechanisms of lung injury: from bench to bedside
Year: 2003
Exhaled breath condensate biomarkers in COPD
Source: Eur Respir J 2008; 32: 472-486
Year: 2008
NMR-based metabolomics of exhaled breath condensate for assessing the effects of inhaled corticosteroids in COPD patients
Source: International Congress 2017 – Management of COPD
Year: 2017
Metabolomic/proteomic analysis of biomarkers in exhaled breath condensates
Source: Annual Congress 2008 - PG8 - Cellular and molecular technologies of today - treatments of tomorrow
Year: 2008
Exhaled breath analysis by ion mobility spectrometry in children with asthma and cystic fibrosis
Source: International Congress 2018 – Cystic fibrosis in paediatric patients: current research
Year: 2018
Is NMR-based metabolomic analysis of exhaled breath condensate accurate?
Source: Eur Respir J 2011; 37: 468
Year: 2011
Exhaled breath condensate for evaluation of inflammation in COPD patients
Source: Eur Respir J 2006; 28: Suppl. 50, 35s
Year: 2006
Differential diagnosis between newly diagnosed asthma and COPD using exhaled breath condensate metabolomics: a pilot study
Source: Eur Respir J, 51 (3) 1701825; 10.1183/13993003.01825-2017
Year: 2018
Inflammatory markers in the exhaled breath condensate from patients with pulmonary sarcoidosis: comparison with BALF
Source: Eur Respir J 2006; 28: Suppl. 50, 353s
Year: 2006
Phenotyping of patients with COPD from exhaled air by ion mobility spectrometry
Source: Annual Congress 2012 - COPD monitoring in stable disease and during exacerbation
Year: 2012
The application of mass spectrometry to the analysis and characterization of protein and peptide composition in exhaled breath condensate of pneumo-oncological diseased persons
Source: Annual Congress 2011 - Bronchial hyperresponsiveness and exhaled and sputum biomarkers
Year: 2011
Prediction of CF exacerbations by FeNO and non-invasive inflammatory markers in exhaled breath condensate
Source: Annual Congress 2008 - Cystic fibrosis: novel aspects of airway function and inflammation
Year: 2008
Exhaled breath condensate: metabolomics
Source: Eur Respir Monogr 2010; 49: 231-236
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept